Ability Pharma
Edifici Eureka – Campus de la UAB
Bellaterra
Catalonia
08193
Website: http://www.abilitypharma.com/
Email: contact@abilitypharma.com
About Ability Pharma
Ability Pharmaceuticals is a clinical stage drug discovery and development biopharmaceutical company headquartered in Bellaterra (Barcelona), Catalonia, Spain.YEAR FOUNDED:
2009
LEADERSHIP:
Founder and CEO: Carles Domènechi
JOBS:
Please click here for Ability Pharma job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
FOLLOW ABILITY PHARMA:
Tweets by Ability Pharma
6 articles about Ability Pharma
-
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer
3/11/2024
The Catalan biopharmaceutical company Ability Pharmaceuticals, announces a €7M investment from a European-Canadian syndicate of life sciences investors, including CTI Life Sciences Fund, Inveready, the EIC Fund, Fitalent and CDTI Innvierte.
-
AbilityPharma Announces FDA Approval of IND for Phase II Trial of ABTL0812 in Patients With Endometrial Cancer or Squamous Non-Small Cell Lung Cancer
12/13/2017
The trial is ongoing in Europe, where a total of 80 patients will be enrolled.
-
Ability Pharma Announces The Approval From The French Medicines Agency ANSM To Initiate A Phase I/IIa Clinical Trial With ABTL0812 To Treat Patients With Endometrial Cancer Or Squamous Lung Cancer As First-Line Therapy In France
10/5/2017
-
Ability Pharma Announces EMA-Orphan Drug Designation For ABTL0812 In Pancreatic Cancer
9/18/2017
-
Ability Pharma Announces Orphan Drug Designation In The US For ABTL0812 In Pancreatic Cancer
12/14/2016
-
Ability Pharma Initiates Phase 2 Combination Trial With ABTL0812 As First Line Therapy In Patients With Endometrial Or Squamous Lung Cancer Patients
11/22/2016